5 Continental Cannabis Funds To Keep Your Eye On

Vancouver-based Canaccord Genuity (TSE:CF) is the largest underwriter of stock offerings for cannabis-related businesses. The company recently appointed a head of European cannabis investment banking. Could this be a sign that the boom in cannabis stocks in North America is spreading over the pond?

Currently the European cannabis space is tiny. The biggest player is London’s Sativa Investments Plc (LON:SATI) with a market capitalization of around $33.6 million USD. Compare this to Canopy Growth Corp. (TSE:WEED) in Canada with a market capitalization of over of $16 billion, or Aurora Cannabis Inc. (TSE:ACB) and Tilray Inc. (NASDAQ:TLRY) which are worth more than $7 billion each and you see how tiny the European cannabis space is.

Despite this there is huge opportunities in European cannabis. Sticking just to the medical market, cannabis is a hundred million dollar a year business. European medicinal cannabis sales might reach 450 million euros per year by 2022 according to an analyst at Canaccord. The CBD market on the other hand will hit 650 million euros by 2022. In Europe medical Cannabis is legal in Germany, Greece, Portugal, Norway, Romania, Poland, Spain, Denmark, Italy, Lithuania, Luxembourg, North Macedonia, Malta, the Czech Republic, the United Kingdom, Ireland and the Netherlands.

Sativa Investments PLC (LON:SATI)

Sativa operates as an investment company in the medical cannabis market. Recently the company has revealed it has plans to become one of the first seed-to-consumer cannabis business in the United Kingdom. The company will wholly own and be involved in the “production, testing and compliance, research & development including pharmacology, commercialization and sales & marketing of medicinal cannabis and cannabidiol products.”

Ananda Developments PLC (NEX:ANA)

Ananda Developments was created to invest in the growing market for medicinal or therapeutic Cannabis derivatives, or related products. The fund is interested in investing in products which contain cannabis or hemp derived cannabinoids. The company’s investment strategy is to invest in “companies, projects or products that are either progressing medicinal or therapeutic Cannabis research and development, or are developing or have already developed, products that contain Cannabis derived cannabinoids and require funding to progress work plans or commercialise products.”

Investment group High Growth Capital would provide the third investment fund on this list, as it pivoted to the cannabis space away from sports data, but it has since abandoned these plans. The cannabis space isn’t for everyone!

I Swear Officer, It’s For My Dog

Gour Medical AG (EPA:MLGML) is a Paris-based company that makes medicine for pets. Recently the company raised a round of funding to help finance its shift to focus on medical cannabis for animals.

Shifting Into Cannabis-Gear

Spinnaker Opportunities PLC (LON:SOP), a London listed cash-shell, recently announced the takeover of privately held Kanabo Research Ltd. Kanabo develops formulations of medical cannabis oil. The company also has distribution rights for a pharmaceutical-quality vaporizer.

If You Can’t Beat ‘Em, Buy ‘Em  

German pharmaceutical firm Dermapharm Holding SE (FRA:DMP), based in Gruenwald, recently entered in an agreement to buy a stake in a private Dutch firm that produces medical cannabis for pharmaceutical use. The shares in Dermapharm surged on initial announcement of the news.

Featured image courtesy of Shutterstock.